Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

35.55 +0.16 (+0.47%)

Streaming Delayed Price Updated: 9:35 AM EDT, Jul 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

33 34 Next >

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 ↗

July 18, 2026

Viking's latest program seeks to push the envelope in weight loss efficacy.

Via The Motley Fool

Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes." ↗

July 18, 2026

Wall Street analysts are highly bullish on Viking Therapeutics, not least because of its promising weight-loss drug, with ongoing and upcoming phase 3 trials.

Via The Motley Fool

This GLP-1 Stock Could Double by 2030. Here's Why ↗

July 16, 2026

Investors need to ask tough questions before initiating a position in this biotech company.

Via The Motley Fool

Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗

July 11, 2026

There are good reasons to invest in Lilly and to hold off.

Via The Motley Fool

Here’s How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 10 Years ↗

July 10, 2026

Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 10 years by 26.85% on an annualized basis producing an average annual return of 40.15%. Currently, Viking Therapeutics has a...

Via Benzinga

Is This Biotech Stock a Buy After Its Massive Rally? ↗

July 09, 2026

This biotech has a powerful growth story, but one competitive threat could reshape the entire investment case before the payoff arrives.

Via The Motley Fool

Is It Too Late to Buy Eli Lilly? ↗

July 08, 2026

The stock has soared 400% in recent years.

Via The Motley Fool

CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? ↗

July 07, 2026

One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.

Via The Motley Fool

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

July 06, 2026

One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.

Via The Motley Fool

Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? ↗

July 06, 2026

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

Via The Motley Fool

How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? ↗

July 05, 2026

This biotech might have a bright future, but it'll need to survive against the incumbents to do so.

Via The Motley Fool

Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying ↗

July 04, 2026

The stock is known to soar on good news.

Via The Motley Fool

Here's Why Viking Therapeutics Stock Surged Higher in June ↗

July 03, 2026

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.

Via The Motley Fool

Is Viking Therapeutics Stock Going to $100? ↗

July 01, 2026

That would be an impressive run if it could get there soon.

Via The Motley Fool

Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗

June 29, 2026

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Via The Motley Fool

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 26, 2026

Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare.

Via The Motley Fool

Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy? ↗

June 23, 2026

The GLP-1 drug market is massive and still growing fast. Investing in a promising growth stock in the space could lead to significant returns.

Via The Motley Fool

Is Viking Therapeutics Stock a No-Brainer Buy Below $35? ↗

June 23, 2026

The drugmaker is looking to challenge the leaders in the weight loss market.

Via The Motley Fool

Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk ↗

June 22, 2026

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

Via The Motley Fool

Set It and Forget It: 2 Consumer Stocks to Hold for the Next 20 Years ↗

June 22, 2026

Shoppers keep coming back to these companies.

Via The Motley Fool

Topics Artificial Intelligence

Is Viking Therapeutics Stock Going to $100? ↗

June 12, 2026

Viking stock is known for soaring after positive news.

Via The Motley Fool

Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188% ↗

June 10, 2026

If you look beyond the upside potential, there's still plenty of risk to navigate past.

Via The Motley Fool

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't ↗

June 03, 2026

This particular sector may suit cautious and aggressive investors.

Via The Motley Fool

Bull vs. Bear: The Quick Take on Viking Therapeutics Stock ↗

June 03, 2026

The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.

Via The Motley Fool

Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down ↗

June 02, 2026

An upcoming trial result could change how investors think about the weight-loss drug market.

Via The Motley Fool

The Smartest Growth Stocks to Buy With $2,000 Right Now ↗

May 30, 2026

Most of the market's best-known growth names are overbought at this time. That's not the case for several off-the-radar alternatives.

Via The Motley Fool

Topics Artificial Intelligence

Prediction: These 2 Obesity Drug Stocks Could Double in 2026 ↗

May 26, 2026

These players are seeing exciting results in clinical trials.

Via The Motley Fool

Don't Buy Viking Therapeutics Stock Until You Read This ↗

May 25, 2026

It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars.

Via The Motley Fool

Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know. ↗

May 25, 2026

The pharma giant is taking steps to expand its portfolio.

Via The Motley Fool

Is Viking Therapeutics a Top Takeover Target? ↗

May 23, 2026

Viking's strong obesity drug data continues fueling acquisition speculation.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.